Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07535437 · ClinicalTrials.gov registry record · Phase 1
A Study of Ivonescimab in Combination With Dato-DXd or Osimertinib in People With Non-Small Cell Lung Cancer
A Phase 1 study, sponsored by Memorial Sloan Kettering Cancer Center.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 66
- Enrollment target
NCT07535437: Recruiting Phase 1 study, sponsored by Memorial Sloan Kettering Cancer Center.
NCT07535437 is a Phase 1 study that is actively recruiting participants, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 66 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07535437, a Phase 1 study, is actively recruiting participants, sponsored by Memorial Sloan Kettering Cancer Center.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 66 participants
- Enrollment target
Study Summary
The researchers are doing this study to find out whether ivonescimab in combination with datopotamab deruxtecan- (Dato-DXd) or osimertinib are safe and effective treatments in people with non-small cell lung cancer (NSCLC) that has an EGFR mutation. The researchers will test different doses of the Dato-DXd or osimertinib with an unchanging (fixed) dose of ivonescimab to find the best dose that causes few or mild side effects in participants. Once the dose is found the researchers will test ivonescimab with Dato-DXd or osimertinib in a new group of participants to see if it is effective in treating their NSCLC with an EGFR mutation.
Interventions
- DRUG Osimertinib
- DRUG Ivonescimab
- DRUG Dato-DXd
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 66 participants |
| Start Date | 2026-04-09 |
| Est. Completion | 2028-04 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07535437
The ClinicalTrials.gov registry entry for NCT07535437 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 66 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Memorial Sloan Kettering Cancer Center, which has 1,884 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Osimertinib is the first listed.
NCT07535437 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07535437 about?
NCT07535437 is a clinical study titled "A Study of Ivonescimab in Combination With Dato-DXd or Osimertinib in People With Non-Small Cell Lung Cancer". The researchers are doing this study to find out whether ivonescimab in combination with datopotamab deruxtecan- (Dato-DXd) or osimertinib are safe and effective treatments in people with non-small cell lung cancer (NSCLC) that has an EGFR mutation. The researchers will test different doses of the D...
What is the current status of trial NCT07535437?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 66 participants. The study started on 2026-04-09. Estimated completion is 2028-04.
What interventions are being tested in trial NCT07535437?
The interventions under investigation include: Osimertinib (DRUG), Ivonescimab (DRUG), Dato-DXd (DRUG).
Who is sponsoring clinical trial NCT07535437?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.